Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted…

• HM
  Hamad Medical Corporation

  Award: MRC-01-18-120
• AL
  American Lebanese Syrian Associated Charities
• SM
  Sidra Medicine

  Awards: SDR400105, SDR400175
• DO
  Department of Biotechnology, Ministry of Science and Technology, India

  Award: BT/HRD/35/02/2006
• QN
  Qatar National Library
• MR
  Medical Research Council
• SA
  Science and Engineering Research Board